Search Results

Business

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy

Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy.

October 20, 2022

·

13 min read

Business

Takeda Adds Potential First-in-Class Celiac Treatment to Repertoire

Takeda, Zedira and Dr. Falk Pharma will collaborate to develop ZED1227/TAK-227, a potential first-in-class investigational therapy for the treatment of celiac disease, Takeda announced Thursday.

October 20, 2022

·

1 min read

Business

Cooperation Between Zedira And Cardiff University - Transglutaminase 6 Is The Focus Of New Research Into Ataxia

September 22, 2015

·

3 min read

Zedira Receives Further Funding To Develop Factor XIIIa-Blockers For Safe Anticogulation

February 12, 2015

·

1 min read

Drug Development

Dr. Falk Pharma And Zedira Enter Phase I Clinical Trials For A Celiac Disease Drug

March 13, 2015

·

2 min read

Zedira Release: Structure of Active Coagulation Factor XIII Published – Milestone on the Way to Safe Anticoagulation October 14th, Darmstadt, Germany

October 14, 2013

·

1 min read

Business

Takeda Puts Up $1B-Plus for Hutchmed’s Colorectal Cancer Drug

Takeda entered into an exclusive licensing agreement with Hutchmed Limited to develop its colorectal cancer candidate, fruquintinib, beyond mainland China, Hong Kong and Macau.

January 23, 2023

·

2 min read

·

Tristan Manalac

Celiac Disease Market: Increase in Demand for Advance Treatment to Drive the Market

The global celiac disease market is prophesied to rake in a heavy demand on account of three decisive factors such as healthy government initiatives, prevalence of the disease, and increased consumption of foods containing gluten.

April 21, 2021

·

5 min read